Two Sigma Advisers
ALDX icon

Two Sigma Advisers’s Aldeyra Therapeutics ALDX Stock Holding History

Two Sigma Advisers’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-121,900
Closed -$631K – 75
2025
Q4 		$631K Sell
121,900
-62,200
-34% -$320K ﹤0.01% 1687
2025
Q3 		$961K Buy
184,100
+153,300
+498% +$799K ﹤0.01% 1480
2025
Q2 		$118K Sell
30,800
-2,300
-7% -$5.95K ﹤0.01% 2191
2025
Q1 		$190K Sell
33,100
-92,200
-74% -$545K ﹤0.01% 2151
2024
Q4 		$625K Sell
125,300
-84,000
-40% -$431K ﹤0.01% 1687
2024
Q3 		$1.13M Sell
209,300
-73,600
-26% -$350K ﹤0.01% 1358
2024
Q2 		$936K Sell
282,900
-92,000
-25% -$360K ﹤0.01% 1583
2024
Q1 		$1.23M Buy
374,900
+23,500
+7% +$77.3K ﹤0.01% 1473
2023
Q4 		$1.23M Sell
351,400
-69,500
-17% -$214K ﹤0.01% 1537
2023
Q3 		$2.81M Sell
420,900
-13,100
-3% -$97.2K 0.01% 1013
2023
Q2 		$3.64M Sell
434,000
-93,900
-18% -$925K 0.01% 902
2023
Q1 		$5.24M Sell
527,900
-62,200
-11% -$440K 0.01% 789
2022
Q4 		$4.11M Sell
590,100
-307,500
-34% -$1.76M 0.01% 862
2022
Q3 		$4.79M Buy
897,600
+10,600
+1% +$63.6K 0.01% 755
2022
Q2 		$3.54M Buy
887,000
+379,300
+75% +$1.3M 0.01% 922
2022
Q1 		$2.26M Sell
507,700
-181,500
-26% -$723K 0.01% 1186
2021
Q4 		$2.76M Sell
689,200
-99,200
-13% -$757K 0.01% 1033
2021
Q3 		$6.92M Sell
788,400
-227,100
-22% -$2.08M 0.02% 645
2021
Q2 		$11.5M Buy
1,015,500
+180,100
+22% +$2.17M 0.03% 510
2021
Q1 		$9.93M Buy
835,400
+162,100
+24% +$1.87M 0.03% 577
2020
Q4 		$4.62M Buy
673,300
+72,700
+12% +$510K 0.01% 856
2020
Q3 		$4.45M Buy
600,600
+523,600
+680% +$3.38M 0.01% 805
2020
Q2 		$321K Buy
77,000
+42,700
+124% +$156K ﹤0.01% 2098
2020
Q1 		$85K Buy
34,300
+24,200
+240% +$109K ﹤0.01% 2317
2019
Q4 		$59K Buy
+10,100
New +$58.3K ﹤0.01% 2286

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers's ALDX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 121,900 shares — an estimated $631K sold.

Two Sigma Advisers first reported a position in ALDX in Q4 2019 and held it in 25 quarters. The position peaked at $11.5M in Q2 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 121,900 Aldeyra Therapeutics shares in Q1 2026, an estimated $631K.
  • Two Sigma Advisers first reported a position in Aldeyra Therapeutics in Q4 2019 and held it in 25 quarters.
  • Two Sigma Advisers's Aldeyra Therapeutics position peaked at $11.5M in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.